ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$11.34 USD
-0.32 (-2.74%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $11.31 -0.03 (-0.26%) 5:38 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SPRY 11.34 -0.32(-2.74%)
Will SPRY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray
Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down
ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
Other News for SPRY
ARS Pharmaceuticals nasal spray for anaphylaxis endorsed in EU
CHMP endorses ARS nasal spray for anaphylaxis
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
ARS Pharmaceuticals: Corporate Update and EURneffy’s Positive Opinion
ARS Pharmaceuticals: EURneffy recommended for approval by CHMP